Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma.
Smits F, Groen K, Levin MD, Stege C, van Kampen RJW, van der Spek E, Bilgin YM, Thielen N, Nijhof IS, Ludwig I, de Waal EGM, Sandberg Y, Kentos A, Timmers GJ, Regelink JC, Westerman M, Heer K, Vekemans MM, Durdu-Rayman N, de Graauw NCHP, Seefat MR, van de Donk NWCJ, Ypma PF, Nasserinejad K, Zweegman S. Smits F, et al. Among authors: seefat mr. Blood. 2024 Nov 22:blood.2024025868. doi: 10.1182/blood.2024025868. Online ahead of print. Blood. 2024. PMID: 39576961
Whole Body Physiologically Based Pharmacokinetic Model to Explain A Patient With Drug-Drug Interaction Between Voriconazole and Flucloxacillin.
Abdullah-Koolmees H, van den Nieuwendijk JF, Hoope SMKT, de Leeuw DC, Franken LGW, Said MM, Seefat MR, Swart EL, Hendrikse NH, Bartelink IH. Abdullah-Koolmees H, et al. Among authors: seefat mr. Eur J Drug Metab Pharmacokinet. 2024 Nov;49(6):689-699. doi: 10.1007/s13318-024-00916-1. Epub 2024 Sep 14. Eur J Drug Metab Pharmacokinet. 2024. PMID: 39271639 Free PMC article.
Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes.
Groen K, Smits F, Nasserinejad K, Levin MD, Regelink JC, Timmers GJ, de Waal EGM, Westerman M, Velders GA, de Heer K, Leys RBL, van Kampen RJW, Stege CAM, Seefat MR, Nijhof IS, van der Spek E, Klein SK, van de Donk NWCJ, Ypma PF, Zweegman S. Groen K, et al. Among authors: seefat mr. Hemasphere. 2024 Jul 4;8(7):e85. doi: 10.1002/hem3.85. eCollection 2024 Jul. Hemasphere. 2024. PMID: 38966208 Free PMC article. No abstract available.
Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial.
Seefat MR, Stege CAM, Lissenberg-Witte BI, Levin MD, Timmers GJ, Hoogendoorn M, Ypma PF, Klein SK, Velders GA, Westerman M, Strobbe L, Durdu-Rayman N, Davidis-van Schoonhoven MA, van Kampen RJW, Dijk AC, Koster A, Silbermann MH, van der Spek E, Beeker A, Erjavec Z, de Graauw NCHP, Leys MBL, Sonneveld P, van de Donk NWCJ, Nasserinejad K, Blommestein HM, Cucchi DGJ, Zweegman S. Seefat MR, et al. Eur J Cancer. 2024 Aug;207:114153. doi: 10.1016/j.ejca.2024.114153. Epub 2024 Jun 6. Eur J Cancer. 2024. PMID: 38870747 Free article. Clinical Trial.
Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13.
Groen K, Schjesvold FH, van der Holt B, Levin MD, Seefat MR, Hansson M, Leys MBL, Regelink JC, Waage A, Szatkowski D, Axelsson P, Hieu Do T, Svirskaite A, van der Spek E, Haukas E, Knut-Bojanowska D, Ypma PF, Blimark CH, Mellqvist UH, van de Donk NWCJ, Sonneveld P, Klostergaard A, Vangsted AJ, Abildgaard N, Zweegman S. Groen K, et al. Among authors: seefat mr. Hemasphere. 2023 Aug 30;7(9):e940. doi: 10.1097/HS9.0000000000000940. eCollection 2023 Sep. Hemasphere. 2023. PMID: 37663673 Free PMC article. No abstract available.